Non-clinical pharmacology research of PD-29875, first-in-class Claudin 18.2-targeting radiotheranostic peptide, in pancreatic cancer models.
用户sToGMn7iJdc8
13小时前
9
10
求助中
帖子自动结束时间: 2025-12-12 20:55:09
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://jnm.snmjournals.org/content/66/supplement_1/251181.abstract
其他信息:
Y Sato, S Tsuchida, Y Mizukoshi, H Inaba, S Kato…
2025
jnm.snmjournals.org
… feasibility of PD-29875 for … that PD-29875 was internalized in BxPC3-CLDN18.2 cells but not BxPC3 cells. In in vivo biodistribution experiments, 64 Cu-PD-29875 and 177 Lu-PD-29875 …
